Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia. / Drago, Antonio; De Ponti, Fabrizio; Boriani, Giuseppe; De Ronchi, Diana; Serretti, Alessandro.

I: Current Medicinal Chemistry, Bind 15, Nr. 24, 2008, s. 2472-517.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Drago, A, De Ponti, F, Boriani, G, De Ronchi, D & Serretti, A 2008, 'Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia', Current Medicinal Chemistry, bind 15, nr. 24, s. 2472-517.

APA

Drago, A., De Ponti, F., Boriani, G., De Ronchi, D., & Serretti, A. (2008). Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia. Current Medicinal Chemistry, 15(24), 2472-517.

CBE

Drago A, De Ponti F, Boriani G, De Ronchi D, Serretti A. 2008. Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia. Current Medicinal Chemistry. 15(24):2472-517.

MLA

Drago, Antonio o.a.. "Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia". Current Medicinal Chemistry. 2008, 15(24). 2472-517.

Vancouver

Drago A, De Ponti F, Boriani G, De Ronchi D, Serretti A. Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia. Current Medicinal Chemistry. 2008;15(24):2472-517.

Author

Drago, Antonio ; De Ponti, Fabrizio ; Boriani, Giuseppe ; De Ronchi, Diana ; Serretti, Alessandro. / Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia. I: Current Medicinal Chemistry. 2008 ; Bind 15, Nr. 24. s. 2472-517.

Bibtex

@article{a5bc13e87a394a3a86e513ef1a558e38,
title = "Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia",
abstract = "Antidepressants and antipsychotics may affect several ion channels involved in the control of cardiac action potential and be proarrhythmic. In this field, accurate understanding of genetics, which per se is a non-controllable risk factor, may help clinicians to prevent life-threatening side effects. So far, a number of genes have been associated with arrhythmia: SCN5A, SCN4B, CACNL1AC, KCNH2, KCNQ1, KCNE1, ANK2, ALG10, KCNJ2, KCNE2, RYR2, KCND3, KCND2, ACE, NOS1AP, CASQ2 and Rad. These genes represent good candidates for the definition of a genetic pro-arrhythmic profile. A genetic analysis of these targets is provided and their possible pathophysiological role in arrhythmias is discussed. Special attention is devoted to the interactions between these genes and new generation antidepressants and antipsychotics. A list of relevant rare mutations within the selected genes is presented, together with a complete list of Tag SNPs covering the whole genetic sequence. The aim of this paper is to define a part of the genetic framework responsible for the proarrhythmic effects of antidepressants and antipsychotics. The selected variants, both mutations and polymorphisms, may help in defining a next-to-come genetic assessment to be performed before drug prescription in order to improve drug safety.",
keywords = "Animals, Antidepressive Agents, Antipsychotic Agents, Arrhythmias, Cardiac, Biomarkers, Electrocardiography, Humans, Ion Channels",
author = "Antonio Drago and {De Ponti}, Fabrizio and Giuseppe Boriani and {De Ronchi}, Diana and Alessandro Serretti",
year = "2008",
language = "English",
volume = "15",
pages = "2472--517",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers Ltd.",
number = "24",

}

RIS

TY - JOUR

T1 - Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia

AU - Drago, Antonio

AU - De Ponti, Fabrizio

AU - Boriani, Giuseppe

AU - De Ronchi, Diana

AU - Serretti, Alessandro

PY - 2008

Y1 - 2008

N2 - Antidepressants and antipsychotics may affect several ion channels involved in the control of cardiac action potential and be proarrhythmic. In this field, accurate understanding of genetics, which per se is a non-controllable risk factor, may help clinicians to prevent life-threatening side effects. So far, a number of genes have been associated with arrhythmia: SCN5A, SCN4B, CACNL1AC, KCNH2, KCNQ1, KCNE1, ANK2, ALG10, KCNJ2, KCNE2, RYR2, KCND3, KCND2, ACE, NOS1AP, CASQ2 and Rad. These genes represent good candidates for the definition of a genetic pro-arrhythmic profile. A genetic analysis of these targets is provided and their possible pathophysiological role in arrhythmias is discussed. Special attention is devoted to the interactions between these genes and new generation antidepressants and antipsychotics. A list of relevant rare mutations within the selected genes is presented, together with a complete list of Tag SNPs covering the whole genetic sequence. The aim of this paper is to define a part of the genetic framework responsible for the proarrhythmic effects of antidepressants and antipsychotics. The selected variants, both mutations and polymorphisms, may help in defining a next-to-come genetic assessment to be performed before drug prescription in order to improve drug safety.

AB - Antidepressants and antipsychotics may affect several ion channels involved in the control of cardiac action potential and be proarrhythmic. In this field, accurate understanding of genetics, which per se is a non-controllable risk factor, may help clinicians to prevent life-threatening side effects. So far, a number of genes have been associated with arrhythmia: SCN5A, SCN4B, CACNL1AC, KCNH2, KCNQ1, KCNE1, ANK2, ALG10, KCNJ2, KCNE2, RYR2, KCND3, KCND2, ACE, NOS1AP, CASQ2 and Rad. These genes represent good candidates for the definition of a genetic pro-arrhythmic profile. A genetic analysis of these targets is provided and their possible pathophysiological role in arrhythmias is discussed. Special attention is devoted to the interactions between these genes and new generation antidepressants and antipsychotics. A list of relevant rare mutations within the selected genes is presented, together with a complete list of Tag SNPs covering the whole genetic sequence. The aim of this paper is to define a part of the genetic framework responsible for the proarrhythmic effects of antidepressants and antipsychotics. The selected variants, both mutations and polymorphisms, may help in defining a next-to-come genetic assessment to be performed before drug prescription in order to improve drug safety.

KW - Animals

KW - Antidepressive Agents

KW - Antipsychotic Agents

KW - Arrhythmias, Cardiac

KW - Biomarkers

KW - Electrocardiography

KW - Humans

KW - Ion Channels

M3 - Journal article

C2 - 18855674

VL - 15

SP - 2472

EP - 2517

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 24

ER -